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Abstract
A new, simple, cost-effective spectrophotometric method was developed for the determination of olanzapine in pharmaceut-
icals. The new method is based on formation of a yellow condensation product with p-dimethylaminobenzaldehyde, followed by
measurement of absorbance at 410 nm.
The reaction variables were optimized at 50 ◦C and 10 min. The reaction occurred at a stoichiometric ratio of 1:1. Absorbance was
found to increase linearly with the concentration of the drug and formed the basis for quantification. The calibration graph was linear
between 5 and 160 g mL−1, and the correlation coefficient was 0.999. The apparent molar absorptivity was 0.6 ×103 L mol−1 cm−1,
and the calculated Sandell sensitivity was 49.50 ng cm−2. The limits of detection and quantification were 6.6 and 20 g mL−1,
respectively. The method was validated in terms of accuracy, precision and reproducibility. The overall recovery was 98.4–101.5%,
with an error of less than 1.7%.
The proposed method was applied to the analysis of olanzapine in pure and dosage form and found to be of equivalent accuracy
and precision to the official Indian Pharmacopoeia high-performance liquid chromatography method. There was no interference
from commonly used excipients.
The method could readily be adapted for use in developing countries where sophisticated equipment is not available.
© 2014 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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1.  Introduction
Olanzapine (2-methyl-4-(4-methyl-1-piperazynyl)-
10H-thieno-[2,3-b][1,5]benzodiazepine) is a thienoben-
zodiazepine derivative. It was first synthesized by Eli∗ Corresponding author. Tel.: +234 803 638 1625.
E-mail addresses: jireade@yahoo.com,
ao.adegoke@mail.ui.edu.ng (O.A. Adegoke).
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Lilly in the United Kingdom in 1982, and the United
States Food and Drug Administration approved olanza-
pine sold by Eli Lilly under the trademark Zyprexa in
late 1996 [1]. Olanzapine is used in adults and adoles-
cents 13 years and over to treat schizophrenia, a mental
illness that causes unusual thinking, loss of interest in
life and strong emotional changes; it is also used to
treat bipolar disorder. Olanzapine is referred to as an
“atypical antipsychotic” because it works by changing
the activity of certain natural substances in the brain.
It is highly active at surprisingly low doses. The olan-
zapine molecule has high affinity for two receptors in
the brain, D2 dopamine receptors and the 5HT2 sero-
tonin receptor, which are important for maintaining
chemical balance in the brain. The polarity of the olan-
zapine molecule allows it to bind strongly to the protein,
and its anticholinergic, antihistamine and -adrenergic
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locking activity contribute to both its therapeutic and
ts adverse actions, producing fewer negative effects than
ost antipsychotics on the part of the brain designed for
otor skills and coordination of movement. The activity
f olanzapine in a binding assay in vitro was similar to
hat of clozapine.
Olanzapine exists in five possible polymorphic forms
I–V); the polymorphism can be controlled, and the
rug remains stable. It is virtually insoluble in water,
reely soluble in dichloromethane, soluble in acetone
nd in n-propanol, sparingly soluble in 2-butanol and
n acetonitrile and slightly soluble in methanol and in
ehydrated alcohol. Olanzapine is sensitive to acid and
ase hydrolysis, oxidation and humidity [2].
Several methods have been reported for the anal-
sis of olanzapine in pure form, dosage forms or in
ombination with other drugs. These methods include
igh-performance liquid chromatography (HPLC) in
iological fluids and for dosage forms [3–7], gas chro-
atography in human plasma [8] and human tissues
9] and titration in non-aqueous media [10]. Several
pectrophotometric methods have been developed for
etermination of olanzapine in bulk and in formula-
ions. Olanzapine is easily oxidized, and many oxidizing
gents have been used, sometimes in combination with
hromogenic agents like dyes, to improve spectro-
hotometric quantification in the visible region and
o avoid interference from other substances present in
he matrix. Some of the agents reported are potas-
ium hexacyanoferrate(III) [11], N-bromosuccinide and
erium (IV) sulfate in an acidic medium [12], potas-
ium iodate in sulfuric acid [13], iodine monochloride
14], cerium(IV) sulfate as anoxidimetric agent and thio-
yanate, tiron and ferrocyanide for colour formation
15], bromocresol purple and bromothymol blue [16].
 recent spectroscopic method for the determination
f olanzapine, based on simultaneous equations (Verodt
ethod), includes simultaneous determination with flu-
xetine HCl without separation from each other or the
xcipients [1]. A condensation reaction for the determi-
ation of olanzapine with 1,2-naphthoquinone-4-sulfate
s the derivatizing reagent was recently described [17].
n alkaline medium (pH 13), an orange product with λmax
t 454 nm was produced.
Although many of the reported methods are accu-
ate and sensitive, they require the use of sophisticated
quipment and expensive reagents. Some are cumber-
ome, requiring prolonged sample pretreatment, strict
ontrol of pH and long reaction times. An easy, fast,
ost-effective spectrophotometric method for the deter-
ination of olanzapine in bulk drug and tablets is needed
hat could be used for routine quality control of theersity for Science 8 (2014) 248–257 249
drug in resource-limited countries. This was the pri-
mary motivation for this research, in which olanzapine
was determined spectrophotometrically following a con-
densation reaction with p-dimethylaminobenzaldehyde
(DMAB).
2.  Materials  and  Methods
2.1.  Equipment
The ultra-violet–visible (UV–Vis) spectrophotometer
was a Jenway 6405 equipped with 1-cm matched quartz
cells. An analytical balance (Mettler AE 160), a Unis-
cope SM101 thermostat water bath and a PV-1 Grant Bio
vortex mixer were used.
2.2.  Stock  solutions
A 0.3% (w/v) solution of DMAB was prepared by dis-
solving 0.075 g of the crystals in 25 mL of 0.5 M H2SO4.
A 1-mg/mL stock solution was prepared by dissolving
10 mg olanzapine crystals in 10 mL methanol.
2.3.  Evidence  of  condensation  reaction
2.3.1.  Spot  test
A 0.5-mL aliquot of 0.3% DMAB was measured into
a test tube, and 0.5 mL of the olanzapine stock solution
was added and vortex-mixed for 10 s. The yellow adduct
formed was kept at room temperature (30 ◦C) for 5 and
20 min. The procedure was repeated, and samples were
incubated at 70 ◦C for 5 and 20 min. Each determination
was repeated twice.
2.3.2.  Thin-layer  chromatography
Thin-layer chromatography (TLC) assessment was
conducted with ethyl acetate:methanol (9:1) orethyl
acetate:methanol (8:2) as the mobile phase. Pre-coated
TLC plates (GF254 0.2 mm, Merck, Germany) were spot-
ted with freshly prepared stock solutions of olanzapine,
DMAB and the adduct formed between olanzapine and
DMAB, and then developed in chromatographic tanks
containing the mobile phases. Spots were visualized
under UV light at 254 nm.
2.4.  Selection  of  analytical  wavelength
A 0.5-mL aliquot of olanzapine stock solution was
added to 0.5 mL of 0.3% DMAB solution in a testtube
and vortex-mixed. The yellow adduct formed was kept at
room temperature for 10 min. The solution was made up
to 5 mL with methanol to terminate the reaction. The
ah Univ250 O.A. Adegoke et al. / Journal of Taib
UV–Vis spectrum of the adduct formed was scanned
at 190–915 nm with methanol as solvent blank; 0.5-mL
aliquots of DMAB and olanzapine solutions in methanol
were scanned separately.
2.5.  Optimization  studies
2.5.1.  Optimization  of  temperature  for  the
condensation  reaction
The method of steepest ascent [18] was adapted for
this assessment. A 0.5-mL aliquot of the drug solution
was added to 0.5 mL DMAB solution in a testtube and
vortex-mixed. The mixture was then incubated at 30 ◦C
for 5 and 20 min. The procedure was repeated at 50 ◦C,
60 ◦C, 70 ◦C and 80 ◦C. In each case, 4 mL of methanol
were added to terminate the reaction after cooling in
ice-cold water. Each determination was performed in
duplicate. The optimum temperature was obtained by
measuring the absorbance of the mixture at maximum
wavelength at each temperature.
2.5.2.  Optimization  of  time
A 0.5-mL aliquot of olanzapine solution was added
to 0.5 mL of 0.3% DMAB solution in a testtube and
vortex-mixed, then incubated at the selected optimal
temperature for 0, 5, 10, 15, 20 or 30 min. Each reaction
was terminated by making the solution up to 5 mL with
methanol. Absorbance was measured at the maximum
wavelength of absorption.
2.5.3.  Effect  of  concentration  of  acid
The effect of varying the concentration of acid used in
preparing the DMAB solution was determined by prepar-
ing the solution in 0.125, 0.25, 0.5, 1 or 2 mol/L H2SO4.
A 0.5-mL aliquot of the drug solution was added to
0.5 mL DMAB solution at each concentration of acid in
a testtube, vortex-mixed and incubated at optimum tem-
perature and time. The absorbance reading was taken
after addition of 4 mL of methanol.
2.5.4.  Effect  of  reagent  concentration
The effect of varying the concentration of DMAB
was measured with concentrations of 0.1, 0.2, 0.3, 0.4
and 0.5% (w/v) in H2SO4. Under optimal conditions,
after mixing 0.5 mL of each concentration with 0.5 mL
olanzapine solution, the reaction mixture was made up
to 5 mL with methanol. The absorbance of the adduct
formed was determined at λmax.2.5.5. Effect  of  solvent
The effect of the solvent used to terminate the reac-
tion was determined with methanol, ethanol, propan-1-olersity for Science 8 (2014) 248–257
and propan-2-ol. Each was used to make up the reac-
tion mixture to 5 mL when terminating the reaction
after incubation at optimal temperature and time. The
absorbance of the resulting mixtures was read at the
maximum wavelength of absorption. The solvent with
the highest absorbance was considered the most suitable
solvent for terminating the condensation reaction and for
spectroscopic analysis.
2.6.  Stoichiometric  ratio
Job’s method of continuous variation [19] was used.
Equimolar solutions (2.68 ×  10−2 M) of DMAB and
olanzapine were prepared in their respective solvents,
and 0, 0.1, 0.2, 0.3, 0.4. 0.5, 0.6, 0.7, 0.8 or 1 mL DMAB
was added. The solutions were made up to 1 mL with
the drug solution. The mixtures were incubated at the
optimum temperature and time, made up to 5 mL with
methanol, and the absorbance readings were taken at the
optimal wavelength of absorption.
2.7.  Validation  studies
Calibration curves were prepared for olanzap-
ine reacted with DMAB in the concentration range
5–160 g mL−1 in methanol. The concentration range
for the analysis was determined by linear regression anal-
ysis of the results for the linearity of response. The range
that gave the best slope, the least intercept and the highest
correlation coefficient was adopted.
The accuracy and repeatability of the new method
were determined on 3 successive days, as stipulated by
the International Conference of Harmonization (ICH)
guidelines [20]. Accuracy was evaluated at three con-
centrations of the drug. The precision of the method
was assessed with replicate samples at each concentra-
tion and then estimated with percentage relative standard
deviation (% coefficient of variation).
The limits of detection and of quantification were
obtained according to the ICH guidelines.
2.8.  Dosage  form  analysis
Three brands of olanzapine were obtained from phar-
macy retail outlets in Ibadan, Nigeria, and assessed for
their content of active ingredient by the new method,
with the Indian Pharmacopoeia HPLC method [21] as
the reference method.2.8.1.  New  method
Twenty tablets were crushed and powdered, and an
amount of the powder equivalent to 10 mg of the drug
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Table 1
Thin layer chromatographic analysis of OLP and reaction products.
Samples Mobile phase; ethyl acetate:methanol (9:1) Mobile phase; ethyl acetate:methanol (8:2)
Rf Values Rf values
OLP-DMAB adduct in methanol 0.61 0.68
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LP in methanol 0.04 
as dissolved in 6 mL methanol. The dispersions were
llowed to sit for 1 h with intermittent swirling and then
ltered. The resulting solution was made up to 10 mL
ith methanol, and 0.25 mL (50 g mL−1) of the solu-
ion was reacted with 0.5 mL DMAB at the optimum
emperature and time. The reaction mixture was made up
o 5 mL with methanol. Six replicates were determined.
.8.2. Ofﬁcial  method
The test solution was prepared by placing 10 tablets of
lanzapine in a volumetric flask with an appropriate vol-
me of acetonitrile. The mixture was then diluted with
.01 mol/L HCl to a final concentration of 0.01% (w/v)
lanzapine. For the reference solution, 10 mg of olanza-
ine were dissolved in about 25 mL of acetonitrile and
iluted to 100 mL with 0.01 M HCl in a volumetric flask.
he content of olanzapine was calculated. Olanzapine
ablets should contain not less than 90% and not more
han 110% of the stated amount of olanzapine.
.9.  Interference  studies
Samples of common excipients were prepared by
dding 5 mg of starch, lactose, talc, gelatin or magnesium
tearate into flasks containing 0.25 mL of olanzapine and
llowed to sit for 10 min. Then, 0.5 mL of DMAB was
dded at optimum temperature and time. The reaction
as terminated by making up to 5 mL with methanol.
he samples were analyzed by the recommended proce-
ures, and the recovery for each sample was calculated.
.  Results  and  discussion
.1.  Evidence  of  condensation  reaction
Evidence of the condensation reaction was estab-
ished by the spot test and TLC analysis of the reaction
ixture. The spot test showed an immediate yellow prod-
ct at room temperature, with no change in colour at
ither room temperature or 70 ◦C after 5 and 20 min.
he reaction time is therefore short, and the colour and
roduct formed are stable even at elevated temperature.0.62
0.09
Normal-phase TLC was carried out by spotting plates
with methanol solutions of adducts formed from olanza-
pine and DMAB in two solvent mixtures. Three spots
were seen on both plates, indicating three different com-
pounds. The retardation factor, Rf, of the adduct was
higher than that of DMAB and different from that of pure
olanzapine, indicating formation of a new compound
(Table 1).
3.2.  Selection  of  analytical  wavelength
The overlaid absorption spectrum of olanzapine and
its condensation product with DMAB in methanol are
shown with that of DMAB alone in Fig. 1. All three
compounds had significant absorption in the UV region.
Most absorption of olanzapine occurred around 250 nm,
while DMAB showed no significant absorption beyond
400 nm. We selected 410 nm as the optimum wavelength
as it gave the greatest difference in absorptivity between
the olanzapine–DMAB adduct and DMAB and fulfilled
the main aim of the study, which was to generate a
coloured adduct with significant absorption in the vis-
ible region with little or no interference from irrelevant
absorption.
A cursory look at the absorption spectra in Fig. 1
shows a hyperchromic shift between the spectrum of the
adduct and that of DMAB alone. This can be attributed
to lack of extensive chromophoric elongation upon for-
mation of the condensation product.
3.3.  Optimization  of  reaction  variables
The optimum conditions of this method that permit a
condensation reaction between olanzapine and DMAB
were established by observing the effect of varying the
parameters one at a time and keeping others constant.
Established optimal conditions were then maintained
throughout the experiment.3.3.1.  Optimization  of  temperature
As seen in Fig. 2, a high temperature is required for
the optimal reaction. As the reaction involves elimina-
tion of a water molecule, higher temperature and the
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Fig. 1. Absorption spectra of (a) olanzapine
presence of an acid in the medium facilitate the reaction.
The absorbance reading increased gradually from 30 ◦C
and was maximum at 60 ◦C, with decreases at 70 ◦C and
80 ◦C. The decrease in absorbance at higher tempera-
tures was probably due to thermal decomposition of the
adduct. As there was no significant difference between
absorbance at 50 ◦C and 60 ◦C, 50 ◦C was chosen as the
optimum temperature. Values at 5 min were lower than
those at 20 min, implying that a longer time is required
for an optimum reaction.
Fig. 2. Optimization of temperature for the condensation reaction.Wav elength (nm)
eaction with DMAB and (b) DMAB alone.
3.3.2.  Time-dependent  variation  of  absorbance  at
50 ◦C
The optimal reaction time was determined at 0, 5, 10,
15, 20 and 30 min at the optimum temperature (Fig. 3).
The highest absorbance was obtained at 10 min, with a
decline thereafter.
3.3.3. Effect  of  concentration  of  acid
The effect of varying the concentration of H2SO4 usedin preparing DMAB was studied at concentrations of
0.125–2 mol/L. Fig. 4 shows an optimal difference in
absorptivity at 0.5 mol/L H2SO4. If the reaction medium
Fig. 3. Time-dependent absorption of the reaction product at 50 ◦C.
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rig. 4. Effect of acid concentration on the condensation reaction.
s too acidic, the amine becomes protonated and non-
ucleophilic, inhibiting the first stage of nucleophile
ddition to the carbonyl. Nevertheless, there must be suf-
cient acid to protonate the carbinolamine so that water,
ather than the much more basic hydroxyl ion, is the leav-
ng group. This explains why lower acid concentrations
ives lower absorbance values. The stability of the Schiff
ase formed depends on the concentration of the acid,
nd higher acid concentrations (>0.5 mol/L) catalyze
reakdown of the product. Our finding that 0.5 mol/L
2SO4 is the optimum acid concentration for prepar-
ng DMAB stock solution for the condensation reaction
s in agreement with the report that this concentration
f H2SO4 is optimal in determining hydralazine with
MAB as the condensation reagent [22].
.3.4. Effect  of  reagent  concentration
The effect of DMAB concentration on the conden-
ation reaction with olanzapine was investigated by
arying the DMAB concentration from 0.1 to 0.5%
n 0.5 mol/L H2SO4. The optimal concentration was
ound to be 0.4% (Fig. 5). Increasing absorbance values
ere observed with increasing concentrations of DMAB,
ndicating that the reaction was not complete at concen-
rations less than 0.4%; the decrease in absorbance above
.5% suggests that the presence of DMAB has reached
 saturable level.
.3.5.  Effect  of  diluting  solvent
The diluting solvents methanol, ethanol, propan-1-olnd propan-2-ol were investigated to select the optimal
olvent for measurement at optimal temperature, time,
eagent concentration and acid concentration. IncreasingFig. 5. Effect of reagent (DMAB) concentration on the reaction.
values were found for propan-2-ol < ethanol < propan-1-
ol < methanol.
The stability of the product formed depends on the
rate at which the expunged water is removed as soon
as it is formed. Methanol is more effective in removing
water, thereby stabilizing the molecule and shifting the
equilibrium towards formation of the Schiff base. Thus,
methanol was the optimal diluting solvent for adduct
formation.
3.4.  Stoichiometry  and  reaction  mechanism
The absorbance of the adduct formed varied with the
stoichiometric ratio of the drug and DMAB (Fig. 6). A
mole ratio of 1:1 gave the highest absorbance value and
was therefore selected as the optimal ratio for subsequent
determinations. This result confirms that olanzapine has
only one centre (secondary amino group) available for
the condensation reaction with DMAB.
3.4.1. Proposed  reaction  mechanism
DMAB has been reported to react with compounds
with secondary amine derivatives, such as ranitidine
hydrochloride [23]. The secondary amine site in the
diazepine ring of the olanzapine molecule reacts with
the electron-deficient centre of DMAB, as proposed in
Scheme 1. When an aldehyde with an -hydrogen reacts
with a secondary amine, the resulting product is an enam-
ine, a relatively stable compound with a carbon–carbon
double bond and an amino functional group. Unlike pri-
mary amines, the carbinolamine intermediate does not
form a C N bond because there is no hydrogen bonded
254 O.A. Adegoke et al. / Journal of Taibah University for Science 8 (2014) 248–257
S N
N
H
H3C
N
N
H3C
OH
N
H3C CH3
OLANZAPINE
S
N+
N
H3C
N
N
H3C
N
H3C CH3
S N
N
H3C
N
N
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H3C
p-DMAB imminium  ion
densatioScheme 1. Proposed mechanism for the con
to the positively charged nitrogen to be eliminated. A
stable compound is obtained by removing a proton from
the -carbon of the compound forming the C C bond of
the enamine. This was confirmed by the finding that the
stoichiometry of the reaction is 1:1, which confirms that
only one site in the olanzapine molecule has an amino
group available for reaction with DMAB. As carbonyls
react only with primary or secondary amino groups, side
reactions are not expected.3.5.  Validation  of  the  proposed  method
The method was validated according to the ICH
guidelines for validation of analytical procedures,Enamine
n reaction between olanzapine and DMAB.
including Sandell’s sensitivity, linearity, range, accuracy
and precision and limits of detection and quantification.
3.5.1. Calibration  curve
Calibration curves were prepared under the estab-
lished conditions, by plotting absorbance as a function
of the corresponding concentrations on each of 3 con-
secutive days. A linear relation was observed between
absorbance at 410 nm and concentrations of olanzap-
ine in the range 5–160 g mL−1. Linear regression was
obtained for the reaction between DMAB and olan-
zapine, with a correlation coefficient of 0.999. The
absorbance increased linearly with increasing concen-
tration of the drug. Molar absorptivity (how effectively
a substance can absorb light of appropriate wavelength)
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apine.
s calculated from the calibration curve. The values are
resented in Table 2.
.5.2.  Limit  of  detection  and  limit  of  quantiﬁcation
The limit of detection is the smallest amount of an
nalyte in a sample that can be detected but not nec-
ssarily quantified, while the limit of quantification is
he smallest amount of an analyte in a sample that can
e determined quantitatively with suitable precision and
able 2
uantitative parameters for the performance of the proposed method.
arameter Value
orking wavelength, nm 410
olour stability, h 24
inear range, g mL−1 5–160
olar absorptivity, L mol−1 cm−1 0.6 × 103
andell sensitivity, ng cm−2 49.50
imit of detection, g mL−1 6.6
imit of quantification, g mL−1 20
alibration curve parametersa
ntercept (a) 0.00084
95% confidence interval for intercept 0.00084 ± 0.013
lope (b) 0.002
95% confidence interval for slope 0.002 ± 0.000072
orrelation coefficient (r) 0.9999
tandard deviation of b (Sb) 2.8 × 10−5
tandard deviation of a (Sa) 5.15 × 10−3
a y = bx + a, where y is absorbance, x is concentration.ersity for Science 8 (2014) 248–257 255
accuracy. These parameters were determined according
to the ICH guidelines from the expressions:
LOD =  3.3σ
s
and LOQ = 10σ
s
where σ  is the standard deviation of the blank signals,
and s is the slope of the calibration graph. The results are
presented in Table 2.
3.5.3. Accuracy  and  precision  of  the  new  method
The accuracy and precision of the method
were assessed at three concentrations (7.5, 30 and
90 g mL−1) of olanzapine within the working limits
under optimum conditions in four replicates on the same
day (intra-day) and on 3 consecutive days (inter-day).
Accuracy is reported as percentage recovery, express-
ing the closeness between the true value and the found
value. The accuracy of our method was evaluated as
the percentage relative error between the measured and
actual concentrations of the drug. Precision expresses
variation in relative standard deviation. The precision of
our method was calculated in terms of repeatability and
intermediate precision (intra-day and inter-day).
Table 3(a) and (b) shows that the percentage rela-
tive error for intra-day accuracy was less than 1.7%,
with recovery of 98.4–101.1%, indicating good accu-
racy. The percentage relative standard deviation for
the intra-day precision did not exceed 3.4%, indicating
good repeatability. For inter-day accuracy, the percent-
age relative error was less than 2%, with recovery of
98.89–101.5%. The percentage relative standard devia-
tion was 0.8–1.94%, indicating good reproducibility.
Recovery studies also measure the effectiveness of
sample preparation. The results showed that 50 g mL−1
was the optimal analyte size in routine use of this assay
procedure. The recovery study showed that this method
is adequate for routine analysis of the drug in quality con-
trol laboratories, provided that care is taken in weighing
the sample and preparing the analyte stock solution.
3.6.  Interference  studies
A study of possible interference by common
excipients used in formulation (starch, lactose, talc, mag-
nesium stearate and gelatin) showed interference only
from gelatin. This is due to the breakdown this polypep-
tide by acids and high temperature into amino acids and
other products, which causes dispersion in the mixtures
of drug and gelatin, giving rise to higher absorbance
values.
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Table 3a
Intra-day assessment of accuracy and precision of the new method.
Amount taken ± SD (g mL−1) a Amount found ± SD (g mL−1)a Recovery (%)a RSDb (%) Relative error (%)
7.5 7.38 ± 0.25 98.40 ± 3.34 3.39 1.60
30 30.13 ± 0.48 100.43 ± 1.59 1.58 0.43
90 91.00 ± 1.08 101.04 ± 1.15 1.14 1.11
a Average of four determinations.
b RSD, relative standard deviation.
Table 3b
Three days assessment of accuracy and precision of the new method.
Amount taken ± SD (g mL−1) a Amount found ± SD (g mL−1)a Recovery (%)a RSDb (%) Relative error (%)
7.5 7.46 ± 0.14 99.44 ± 1.93 1.94 0.53
30 29.67 ± 0.49 98.89 ± 1.64 1.66 1.10
90 91.46 ± 0.78 101.50 ± 0.81 0.80 1.62a Average of 12 determinations.
b RSD, relative standard deviation.
3.7.  Application  to  dosage  form  analysis
The proposed method was tested with three commer-
cial brands of tablets containing 10 mg olanzapine active
ingredient. All the samples passed the weight uniformity
test and quantitative determination with the new method
and with the official HPLC method. The label claims of
the content of active ingredient were within the spec-
ified limit of 90–110%. The recoveries obtained with
the HPLC method were higher than with the spectro-
scopic method, showing the greater sensitivity of HPLC
for detecting substances at very low concentrations.
A comparison of the new method with the official
Indian Pharmacopoeia method is shown in Table 4. The
mean recovery, determined as the ratio of the results
obtained with the new method and with the official
method, was 96.69–101%. The percentage error of the
method, determined as the difference between estimated
Table 4
Comparative dosage form analysis using new method and official HPLC meth
Drug
formulations
(10 mg
strength)
New methoda Official methoda
Amount found
(mg)
RSD (%) Amount found
(mg)
RSD
Glenmark UK 9.96 1.51 10.30 2.72
Lanzep 10 10.61 0.85 10.50 2.0 
Olanza 10 10.20 1.57 10.50 2.03
a Mean value, n = 6. Content of OLP stated by Indian Pharmacopoeia range
b % recovery calculated as a ratio of the new method to the official method
c Statistical analyses done between the results obtained from the proposed and reference values, was less than 3.5%. The F  test was
used to estimate the difference in variance between the
two methods, while Student’s t  test was used to com-
pare the mean recovery, with 95% confidence intervals.
The two tests showed non-significant differences in the
precision and accuracy of the two methods. Therefore,
the accuracy and precision of the new method for quan-
titative determination are similar to those of the official
HPLC method, indicating that the DMAB method is a
reliable alternative to the official method for rapid rou-
tine laboratory analysis of olanzapine in pharmaceutical
dosage forms and in bulk.
The proposed DMAB method is simple, accurate and
inexpensive for determining olanzapine in bulk drug and
dosage forms. It is faster than the sophisticated HPLC
technique because clean up and long warm up, which
can make the technique tedious, are not required. The
new method involves use of a simple reagent without
od.
Mean
recovery ± SD
(%)b
Error (%) Statistics (p values)c
 (%) F-test t-test
 96.70 3.40 0.24 0.32
101.05 1.10 0.13 0.32
 97.14 3.0 0.49 0.47
s from 90% to 110%.
.
method and the official method.
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ecourse to extensive extraction procedures or diverse
rganic solvents.
.  Conclusion
The proposed method has advantages over previously
eported visible spectrophotometric methods because of
ts simplicity, rapidity and wider range of concentra-
ion limits. All the analytical reagents are inexpensive,
ave a long shelf life and are readily available in
ny analytical laboratory. It does not require extensive
ample preparation or extraction. The method will be
seful for routine analysis of olanzapine in bulk and
osage form in quality control laboratories. This will be
articularly useful in resource-limited countries where
ophisticated equipment like HPLC may not be readily
vailable.
eferences
[1] K.S. Rubesh, P. Gayathri, N. Duganath, C.H. Kiran, C. Sridhar, K.
Jayaveera, Simultaneous estimation of fluoxetine HCl and olan-
zapine in bulk drug and pharmaceutical formulation by using
UV–visible spectroscopy method, Int. J. Pharm. Sci. Drug Res. 3
(2011) 52.
[2] European Medicines Agency, Pre-authorisation Evaluation of
Medicines for Human Use. Assessment Report for Zypadhera
(International Nonproprietary Name: olanzapine), London, 2008
http://www.ema.europa.eu/docs/en GB/document library/EPAR
Public assessment report/human/000890/WC500054428.pdf
[3] D. Concetta, M. Gaetana, S. Vincenza, S. Edoardo, Deter-
mination of olanzapine in human plasma by reversed-phase
high-performance liquid chromatography with ultraviolet detec-
tion, Ther. Drug Monit. 28 (2006) 388.
[4] M.A. Raggi, G. Casamenti, R. Mandrioli, G. Izzo, E. Kenndler,
Quantitation of olanzapine in tablets by HPLC, CZE, derivative
spectrometry and linear voltammetry, J. Pharm. Biomed. Anal.
23 (2000) 973.
[5] O.V. Olesen, K. Linnet, Determination of olanzapine in serum
by high-performance liquid chromatography using ultraviolet
detection considering the easy oxidability of the compound and
the presence of other psychotropic drugs, J. Chromatogr. B 714
(1998) 309.
[6] S.C. Kasper, E.L. Mattiuz, S.P. Swanso, J.A. Chiu, J.T. Johnson,
C.O. Garner, Determination of olanzapine in human breast milk
by high performance liquid chromatography with electrochemical
detection, J. Chromatogr. B 726 (1999) 203.
[7] M.A. Saracino, O. Gandolf, R.O. Dall’Olio, L. Albers, E. Ken-
ndler, M.A. Raggi, Determination of olanzapine in rat brain using
liquid chromatography with coulometric detection and a rapid
solid-phase extraction procedure, J. Chromatogr. A 1122 (2006)
21.
[ersity for Science 8 (2014) 248–257 257
[8] S. Ulrich, Assay of olanzapine in human plasma by a rapid
and sensitive gas chromatography-nitrogen phosphorus selective
detection (GC-NPD) method: validation and comparison with
high-performance liquid chromatography-coulometric detection,
Ther. Drug Monit. 27 (2005) 463.
[9] C. Vance, M. Lain, Post-mortem tissue concentration of olanza-
pine, J. Anal. Toxicol. 33 (2009) 15.
10] K. Basavaiah, N. Rajendraprasad, K.B. Vinay, Microtitrimet-
ric determination of drug content of pharmaceuticals containing
olanzapine in non-aqueous medium, Chem. Ind. Chem. Eng. Q.
15 (2009) 77.
11] A. Jasinska, E. Nalewajko, Batch and flow injection methods for
the spectrophotometric determination of olanzapine, Anal. Chim.
Acta 508 (2004) 165.
12] A. Krebs, B. Starczewska, H. Puzanowsha-Tarasiewicz, J. Sledz,
Spectrophotometric determination of olanzapine by its oxidation
with N-bromosuccinimide and cerium (IV) sulphate, Anal. Sci.
22 (2006) 829.
13] A.A. Mohamed, Kinetic and maximum absorbance spectro-
photometric methods for the determination of olanzapine,
Monatsh Chem. 139 (2008) 1005.
14] H.D. Revanasiddappa, M.A. Veena, Highly sensitive spec-
trophotometric methods for the determination of olanzapine,
Ecletica Quim. 33 (2008) 47.
15] R. Nagaraju, B. Kanakapura, T. Kalsang, B.K. Vinay, Quantitative
determination of olanzapine in tablets with visible spectropho-
tometry using cerium(IV) sulphate and based on redox and
complexation reactions, Eurasian J. Anal. Chem. 4 (2009) 191.
16] K. Basavaiah, K. Tharpa, N. Rajendraprasad, S.G. Hiriyanna,
K.B. Vinay, Spectrophotometric determination of antipsychotic
drug olanzapine in pharmaceuticals, Jordan J. Chem. 4 (2009)
65.
17] A.A. Elbashir, A.A. Ahmed, S.M.A. Ahmed, H.Y. Aboul-Enein,
1,2-Naphthoquinone-4-sulphonic acid sodium salt (NQS) as an
analytical reagent for the determination pharmaceutical amine by
spectrophotometry, Appl. Spectrosc. Rev. 47 (2012) 219.
18] H.T. Karnes, C. March, Precision, accuracy and data acceptance
criteria in biopharmaceutical analysis, Pharm. Res. 10 (1993)
1420.
19] J. Rose, Advanced Physico-chemical Experiments, Pitman, Lon-
don, 1964, pp. p.54.
20] International Conference on Harmonisation of Technical require-
ments for Registration of Pharmaceuticals for Human Use, ICH
Guidelines Q2(R1), ICH Harmonised Tripartite Guideline. Vali-
dation of Analytical Procedures: Text and Methodology, Geneva,
2005.
21] Indian Pharmacopoeia, Controller of Publications, Ministry of
Health and Family Welfare Government of India, New Delhi,
2007, pp. 857–858.
22] O.A. Adegoke, C.E. Nwoke, Spectrophotometric determina-
tion of hydralazine using p-dimethylaminobenzaldehyde, J. Iran.
Chem. Soc. 5 (2008) 316.23] B. Narayana, K. Ashwini, D.S. Narayana, K. Veena, Spec-
trophotometric determination of ranitidine hydrochloride based
on the reaction with p-dimethylaminobenzaldehyde, Eurasian J.
Anal. Chem. 5 (2010) 63.
